DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 80+ companies ...

For treating NASH, semaglutide is being studied in combination with Akero Therapeutics’ efruxifermin. In June 2023, Akero and Novo reported positive data from the Phase IIb trial showing that ...

In other recent news, Akero Therapeutics has been the focus of numerous analyst upgrades following promising trial results for its NASH treatment. Jefferies analyst Michael Yee raised the price ...

CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), ending development of its lead drug.

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ventyx Biosciences (VTYX – Research Report), ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

Victoria Nash - Drexel Graduate Co-op at Spark Therapeutics (1/3) Victoria Nash - Advice for Graduate Students in Biomedical Engineering (2/3) Victoria Nash - Benefits of Drexel Biomedical Engineering ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and ...